ANAPTYSBIO, INC
ANAB · XNASCIK 1370053fmd_1EN973P273WE8PBA7GW2WNBPKJManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2015 to Sep 30, 2026, 44 periods
| Line item | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 17 | 10 | 5 | 8 | 75 | 63 | 10 | 17 | 91 | 235 |
| Research and development | 15 | 29 | 56 | 99 | 80 | 98 | 89 | 132 | 164 | 136 |
| Total operating expenses | 20 | 39 | 72 | 115 | 99 | 120 | 125 | 182 | 206 | 187 |
| Operating income | (3) | (29) | (67) | (107) | (24) | (57) | (115) | (164) | (115) | 48 |
| Interest expense | 0 | 2 | 2 | 1 | 0 | 0 | – | – | – | – |
| Interest and investment income | 0 | 2 | – | – | – | – | – | – | – | – |
| Other non-operating income (expense) | (1) | (1) | 5 | 10 | 4 | (1) | (14) | 1 | (30) | (61) |
| Income before taxes | (4) | (30) | (62) | (97) | (20) | (58) | (129) | (164) | (145) | (13) |
| Income tax expense | 0 | 0 | (0) | (0) | 0 | 0 | 0 | (0) | 0 | 0 |
| Net income from continuing operations | (4) | (30) | (62) | (97) | (20) | (58) | (129) | (164) | (145) | (13) |
| Net income | (4) | (30) | (62) | (97) | (20) | (58) | (129) | (164) | (145) | (13) |
| Net income to common shareholders | (4) | (30) | (62) | (97) | – | – | – | – | – | – |